Although the approaches used in the treatment of glioma are constantly improving [3], the 5-year survival rate remains unsatisfactory [4]. In a recent study, explorations of tumor immunity and immunotherapy in glioma have resulted in new hope for patients [5]. The tumor microenvironment (TME)...
The RTK-PI3K-AKT-mTOR signaling pathway is central to regulating tumor growth by controlling cell survival, proliferation, protein translation, and motility [171,172]. This pathway is activated in most glioma patients and is influenced by several alterations, such as Phosphatase and Tensin Homolog (...
In the 1990s, the DNA alkylating agent temozolomide was tested and approved by the FDA as a chemotherapeutic agent for the treatment of malignant glioma. Addition of temozolomide to surgical resection and radiotherapy extends median survival to 14.6 months and the 2-year survival rate to 27% compa...
Glioblastoma is the highest-grade, most malignant form of astrocytoma, and it is the most common and aggressive type of human brain tumor, with a 5-year survival rate of only 5% [201]. While not all gliomas may be neural crest-derived, since NCC do give rise to certain populations of ...
Gliomas are aggressive intracranial tumors of the central nervous system with a poor prognosis, high risk of recurrence, and low survival rates. Radiation, surgery, and chemotherapy are traditional cancer therapies. It is very challenging to accurately image and differentiate the malignancy grade of g...
remained a significant predictor of survival time in a final model that included age, surgery, tumor location, WHO subtype, body mass index, CD4 T cell proportion, and an interaction between WHO subtype and NDMI score (Table3). Figure7shows the Kaplan–Meier survival curves for NDMI score spl...
survival ratediagnosisGliomas are the most common primary malignant brain tumor in the United States with previous studies showing the incidence varied by age, sex, and race or ethnicity. Survival after diagnosis has also been shown to vary by these factors. Also, socioeconomic status and its ...
a general-purpose surgical adjunct, FastGlioma provides physicians with real-time, accurate and clinically actionable diagnostic information within seconds of tissue biopsy that can improve the surgical care of patients with brain tumours, thereby increasing patient quality of life and overall survival. ...
1 Despite advances in many types of pediatric and young adult cancers, treatment for brain cancer has proven exceedingly difficult, specifically for high-grade gliomas (HGGs), which have a 5-year survival rate of <15%.2 Previous research has implicated histone H3-3A (Histone 3.3 or H3.3) ...
Functions and pathways affected by key energy metabolism-related gene GLUD1 in IDH-mutant glioma Due to the higher survival rate in IDH-mutant glioma patients (Fig. 1C) and the higher expression in IDH-mutant samples (Fig. 2D), it was necessary to explore the potential functions and pathway...